<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Altman MK</submitter><funding>NCI NIH HHS</funding><pagination>175-83</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4654121</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>369(1)</volume><pubmed_abstract>The regulator of G protein signaling 10 (RGS10) protein is a GTPase activating protein that accelerates the hydrolysis of GTP and therefore canonically inactivates G proteins, ultimately terminating signaling. Rheb is a small GTPase protein that shuttles between its GDP- and GTP-bound forms to activate mTOR. Since RGS10 suppression augments ovarian cancer cell viability, we sought to elucidate the molecular mechanism. Following RGS10 suppression in serum-free conditions, phosphorylation of mTOR, the eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1), p70S6K and S6 Ribosomal Protein appear. Furthermore, suppressing RGS10 increases activated Rheb, suggesting RGS10 antagonizes mTOR signaling via the small G-protein. The effects of RGS10 suppression are enhanced after stimulating cells with the growth factor, lysophosphatidic acid, and reduced with mTOR inhibitors, temsirolimus and INK-128. Suppression of RGS10 leads to an increase in cell proliferation, even in the presence of etoposide. In summary, the RGS10 suppression increases Rheb-GTP and mTOR signaling in ovarian cancer cells. Our results suggest that RGS10 could serve in a novel, and previously unknown, role by accelerating the hydrolysis of GTP from Rheb in ovarian cancer cells.</pubmed_abstract><journal>Cancer letters</journal><pubmed_title>Suppression of the GTPase-activating protein RGS10 increases Rheb-GTP and mTOR signaling in ovarian cancer cells.</pubmed_title><pmcid>PMC4654121</pmcid><funding_grant_id>R15 CA151006</funding_grant_id><funding_grant_id>P30 CA016672</funding_grant_id><funding_grant_id>CA16672</funding_grant_id><funding_grant_id>1R15CA151006-01</funding_grant_id><funding_grant_id>R15 CA176653</funding_grant_id><funding_grant_id>1R15CA176653-01A1</funding_grant_id><pubmed_authors>Tran SK</pubmed_authors><pubmed_authors>Fambrough JM</pubmed_authors><pubmed_authors>Beedle AM</pubmed_authors><pubmed_authors>Altman MK</pubmed_authors><pubmed_authors>Patel MB</pubmed_authors><pubmed_authors>Murph MM</pubmed_authors><pubmed_authors>Jia W</pubmed_authors><pubmed_authors>Hoseinzadeh P</pubmed_authors><pubmed_authors>Alshamrani AA</pubmed_authors><pubmed_authors>Nguyen HT</pubmed_authors></additional><is_claimable>false</is_claimable><name>Suppression of the GTPase-activating protein RGS10 increases Rheb-GTP and mTOR signaling in ovarian cancer cells.</name><description>The regulator of G protein signaling 10 (RGS10) protein is a GTPase activating protein that accelerates the hydrolysis of GTP and therefore canonically inactivates G proteins, ultimately terminating signaling. Rheb is a small GTPase protein that shuttles between its GDP- and GTP-bound forms to activate mTOR. Since RGS10 suppression augments ovarian cancer cell viability, we sought to elucidate the molecular mechanism. Following RGS10 suppression in serum-free conditions, phosphorylation of mTOR, the eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1), p70S6K and S6 Ribosomal Protein appear. Furthermore, suppressing RGS10 increases activated Rheb, suggesting RGS10 antagonizes mTOR signaling via the small G-protein. The effects of RGS10 suppression are enhanced after stimulating cells with the growth factor, lysophosphatidic acid, and reduced with mTOR inhibitors, temsirolimus and INK-128. Suppression of RGS10 leads to an increase in cell proliferation, even in the presence of etoposide. In summary, the RGS10 suppression increases Rheb-GTP and mTOR signaling in ovarian cancer cells. Our results suggest that RGS10 could serve in a novel, and previously unknown, role by accelerating the hydrolysis of GTP from Rheb in ovarian cancer cells.</description><dates><release>2015-01-01T00:00:00Z</release><publication>2015 Dec</publication><modification>2020-10-29T13:07:40Z</modification><creation>2020-10-29T13:07:40Z</creation></dates><accession>S-EPMC4654121</accession><cross_references><pubmed>26319900</pubmed><doi>10.1016/j.canlet.2015.08.012</doi></cross_references></HashMap>